It’s not always necessary to lower a child’s fever, but parents often do. A new poll from Michigan Medicine found that about one-third of parents reach for fever-reducing medicines too quickly. “Often parents worry about their child having a fever and want to do all they can to reduce their temperature. However, they may not be aware that in general the main reason to treat a fever is just to keep their child comfortable,” said Dr. Susan Woolford, co-director of the C.S. Mott Children’s Hospital National Poll on Children’s Health at University of Michigan Health, in Ann Arbor. “Some parents may immediately rush to give their kids medicine, but it’s often better to let the fever run its course,” Woolford said in a university news release. “Lowering a child’s temperature doesn’t typically help cure their illness any faster. In fact, a low-grade fever helps fight off the infection. There’s also the risk of giving too much medication when it’s not needed, which can have side effects.” The poll surveyed nearly 1,400 parents of children aged 12 and under between August and September 2022. The results showed that even though parents recognize the benefits of a low-grade fever for fighting off infection, about one-third would still give their child fever-reducing medication at temperatures below 100.4. Half would do so at a temperature between 100.4 and 101.9,…  read on >  read on >

Natural immunity acquired from a COVID infection provides strong and lasting protection against severe illness if a person becomes reinfected, a new evidence review has concluded. Ten months after a COVID infection, protection against hospitalization and death remains at 89% for Omicron and 90% for earlier variants, according to pooled data from 65 studies conducted in 19 countries. However, protection against reinfection wanes quickly with Omicron, which is the dominant COVID strain at this time, researchers found. After 10 months, a previous case of Omicron provides only 36% protection against a follow-up COVID infection, researchers reported Feb. 16 in The Lancet. The analysis suggests that the level and duration of protection derived from COVID infection is at least on a par with that provided by two doses of the mRNA vaccines developed by Moderna and Pfizer-BioNTech, researchers said. “These findings are not surprising as multiple studies have shown that prior infection confers protection against severe disease, though it may not confer protection against infection in the Omicron era,” said Dr. Amesh Adalja, a senior scholar with the Johns Hopkins Center for Health Security in Baltimore. He was not involved in the research. But because people first infected with the coronavirus run the risk of hospitalization, death and long COVID, researchers concluded that vaccination remains the overall best form of protection against COVID. “The vaccines and…  read on >  read on >

Older people have vaccines available to prevent severe influenza and COVID-19, but there’s been nothing to protect against the third respiratory virus that contributed to this season’s wretched “triple-demic.” Until now. Two major pharmaceutical companies published clinical trial results this week that pave the way for an RSV (respiratory syncytial virus) vaccine to be available for adults by the time next cold and flu season rolls around. “RSV continues to be the last of the major winter respiratory viruses for which we don’t have a vaccine, but as these two articles in the New England Journal of Medicine indicate, we’re getting close,” said Dr. William Schaffner. He is medical director of the National Foundation for Infectious Diseases, in Bethesda, Md. The companies — GlaxoSmithKline (GSK) and Janssen — both have RSV vaccine candidates that can prevent severe illness in seniors, results show. The GSK vaccine provides 94% protection against severe lower respiratory tract RSV, and about 83% protection against lower respiratory tract infections overall, said Dr. Leonard Friedland, vice president and director of scientific affairs and public health for GSK U.S. Vaccines. “We’re very, very pleased and excited because this is the first time that an RSV vaccine has made it through phase 3 and has published data in a peer-reviewed journal,” Friedland said. The Janssen vaccine also provided good protection in a phase 2b…  read on >  read on >

Talk about the stuff of nightmares. You have extremely itchy skin at bedtime, not to mention a pimple-like rash. What is it? Those are fairly clear signs of scabies, a microscopic parasitic infestation where mites burrow under your skin and lay eggs there. Scabies infection comes from prolonged contact, not just a quick brush against someone else’s skin. It can also be passed through bedding or clothing. “Anyone who is diagnosed with scabies, as well as his or her sexual partners and other contacts who have had prolonged skin-to-skin contact with the infested person, should be treated,” the U.S. Centers for Disease Control and Prevention advises. What is scabies? This “human itch mite” lives and lays eggs in the upper layer of the skin, according to the CDC. About 200 million people worldwide have scabies at any one time, including up to 10% of children in poor areas, according to the World Health Organization. Once the eggs hatch, the larvae can travel to the skin’s surface, spreading to other areas or other people, according to the Mayo Clinic. What does scabies look like? It may resemble hives, tiny bites, knots under the skin or even eczema-like scaly patches, according to the American Academy of Dermatology (AAD). Sores may develop from scratching. Under magnification, the mite is creamy-white, has eight legs and a round body. It…  read on >  read on >